Publications

PEER REVIEW PUBLICATIONS:

1. Zipser R, Hoefs JC, Speckart P, Zia P, Horton R: Prostaglandins, modulators of renal function and pressure resistance in chronic liver disease. J Clin Endocrinol Metab 1979;48:895.

2. Hoefs JC, Renner IG, Ashcavai M, Redecker AG: Hepatitis-B surface antigen in pancreatic and billiary secretions. Gastroenterology 1980;79 (2):191-194.

3. Quismorio FP Jr, Kaufman RC, Halle P, Hoefs JC: Immune complexes and crytoproteins in ascitic fluid of patients with alcoholic liver disease. Int Arch of Allergy and Appl Immunology 1981;64:190-194.

4. Hoefs JC, Barnes T, Halle P: Intraperitoneal coagulation in chronic liver disease ascites. Dig Dis & Sci 1981;26(6):518-522.

5. Zipser RD, Kerlin P, Hoefs JC, Zia P, Barg A: Renal Kallikrein excretion in alcoholic cirrhosis: Relationship to other vasoactive systems. Amer Jour of Gastroenterology 1981;75(3):183-187.

6. Hoefs JC: Increase in ascites white blood cell and protein concentration during diuresis in patients with chronic liver disease. Hepatology 1981;1(3):249-254.

7. Pare P, Hoefs JC, Ashcavai M: Determinants of serum bile acids in chronic liver disease. Gastroenterology 1981;81(5):959-964.

8. Hoefs JC: The mechanism of ascitic fluid protein concentration increase during diuresis in patients with chronic liver disease. Amer Jour of Gastroenterology 1981;76(5):423-431.

9. Kaufman RL, Hoefs JC, Quismorio Jr., FP: Immune complexes in the portal and systemic circulation of patients with alcoholic liver disease. Clin Immuno and Immunopath 1982;22:44-54.

10. Hoefs JC, Canawati H, Sapico F, Hopkins R, Weiner J, Montgomerie J: Spontaneous bacterial peritonitis. Hepatology 1982;2(4):399-407.

11. Hoefs JC: Nordlinger et al, Letter to Editor. Response to non-invasive measurement of nutrient portal blood shunting: An experimental study with ursodeoxycholic acid. Hepatology 1983;3(3):464-465.

12. Pare P, Talbot J, Hoefs JC: Serum-ascites albumin concentration gradient: A physiologic approach to the differential diagnosis of ascites. Gastroenterology 1984;85:240-244.

13. Hoefs JC: Serum protein concentration and portal pressure determines the ascitic fluid protein concentration in patients with chronic liver disease. J Lab and Clin Med 1983;102(2):260-273.

14. Hoefs JC, Reynolds TB, Sakimura I, Pare P: A new method for the measurement of intrahepatic shunts. J Lab and Clin Med 1984;103(3):446-461.

15. Runyon BA, Hoefs JC: Ascitic Fluid Analysis in the differentiation of spontaneous bacterial peritonitis from gastrointestinal tract perforation into ascitic fluid. Hepatology 1984;3:447-450.

16. Runyon BA, Hoefs JC: Is the concept of "exudative" ascites useful? Hepatology 1984;4(5):982.

17. Elias AN, Hoefs JC, Parker L, Haw T, and Lifraket ET: Effect of short-term bile duct ligation on peripheral blood steroids urinary PGE2 and the rate of sodium excretion in male rabbits. Gen Pharm 1984;15(5):427-430.

18. Jones G, Tucker K, Waldeck N, Suzuki M, Hoefs JC, Charles MA: Portal blood pressure after intrahepatic megaislet allotransplantation in rats. Transplantation 1984;39:79-80.

19. Hoefs JC, Green G, Reynolds TB, Sakimura I: Mechanism for the abnormal liver scan in acute alcoholic liver injury. Amer Jour of Gastroenterology 1984;79(12):950-958.

20. Runyon BA, Hoefs JC: Culture negative neutrocytic ascites. Hepatology 1984;4:1209-1211.

21. Runyon BA, Hoefs JC: CNNA: To treat or not to treat. (Letter) Hepatology 1985;5(5):911.

22. Lohiya G, Govindarajan S, Hoefs JC, Valinluck B, Maeda W: Prevalence of hepatitis B associated delta-agent among mentally retarded HBsAg carriers. Journal of Infectious Diseases 1985;141:705.

23. Runyon BA, Hoefs JC: Ascitic fluid chemical analysis before, during, and after spontaneous bacterial peritonitis. Hepatology 1985;5:257-259.

24. Runyon BA, Morrissey R, Hoefs JC, Wyle F: Opsonic activity of human ascitic fluid: a potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology1985;5(4):634-637.

25. Hoefs JC, Runyon BA: More on ascitic fluid analysis by Anthony Bokye and William Carrey. (Letter) Hepatology 1985;5(5):526.

26. Lohiya G, Pirkle H, Hoefs JC, Lohiya S: Hepatocellular carcinoma in young mentally retarded HBsAg carriers. Hepatology. 1985;5(5):824-826.

27. Hoefs JC, Aufrichtig D, Lottenberg S, Kanel GC, Donner BS, Ferrari LA, Leeman S, Friedenberg RM: A non-invasive evaluation of hepatic fibrosis using frequency demodulation of ultrasound signals. Digestive Disease and Sciences 1985;31:1046-1055.

28. Aufrichtig D, Lottenberg S, Hoefs J, et al: Frequency demodulation/ultrasound imaging - an evaluation in the liver. Radiology 1986;160(1):59-64.

29. Runyon BA, Hoefs JC: Peritoneal lymphomatosis with ascites: a characterization. Archives of Internal Medicine 1986;146:887-888.

30. Runyon BA, Hoefs JC: Spontaneous vs secondary bacterial peritonitis: differentiation by response of ascitic fluid neutrophil count to antimicrobial therapy. Arch Int Med 1986;146:1563-1565.

31. Duerinckx AJ, Ferrari L, Hoefs JC, Sankar PV, Fleming D, Cole-Beuglet C: Estimation of acoustic attenuation in liver using one megabyte of data and the zero crossings technique. Ultrasonics 1986;24:325-332.

32. Runyon BA, Hoefs JC, Canawati HN: Polymicrobial bacterascites: unique entity in the spectrum of infected ascitic fluid. Arch of Intern Med 1986;146 (11): 2273-2275.

33. Rector WG, Ibarra F, Openshaw K, Hoefs JC: Ascites kinetics in cirrhosis: Relationship to plasma-ascites hydrostatic oncotic balance and intensity of renal sodium retention. J Lab Clin Med 1986;107(5):412-419.

34. Hoefs JC, Glick MM, Meshkinpour H: Glucose intolerance and hepatic, biliary tract and pancreatic dysfunction. Dig Dis 1987;5:78-96.

35. Duerinckx AJ, Rosenberg K, Hoefs JC, Aufrichtig D, Cole-Deuglet C, Kanel G, Lottenberg S, Ferrari L: In-Vivo acoustic attenuation in liver: correlations with histology and blood tests. Ultrasound in Medicine and Biology 1988;14(5):405-413.

36. Rector WG, Hoefs JC, Horsach KF, Everson, Gregory T: Hepatofugal portal flow in cirrhosis: observation on hepatic hemodynamics and the nature of the arterioportal communications. Hepatology 1988;8:16-20.

37. Runyon BA, Morgan TR, Hoefs JC: Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988;8(5):1104-1109.

38. Hoefs JC: Measurement of portal shunting in dogs. Am J of Gastroenterol 1989;84(:296-301.

39. Hoefs JC: Diagnostic paracentesis: a potent clinical tool. Gastroenterology 1990;98:230-236.

40. Hoefs JC, Jonas GM, Sarfeh IJ. Diagnosis and hemodynamic assessment of portal hypertension. Surg Clin North Am 1990;70:269-89.

41. Hoefs JC: Spontaneous Bacterial Peritonitis: Prevention and Therapy. Hepatology 1990;12:776-781.

42. Levenson H, Greensite F, Hoefs JC, Friloux L, Applegate G, Silva E, Kanel G, Buxton R: Fatty Infiltration of the Liver: Quantification with Phase-Contrast MR Imaging at 1.5 T vs Biopsy. AJR 1991;156: 307-312.

43. Said H, Hoefs JC, Reza M, Horne DW: Biotin Transport in Human Liver Basolateral Membrane Vesicles: A Carrier-Mediated, Na+ Gradient-Dependent Process. Gastroenterology 1992;102:2120-2125.

44. Hoefs JC: Globulin Correction of Albumin Gradient: Correlation with Measured Serum to Ascites Colloid Osmotic Pressure Gradients. Hepatology 1992;16:396-403.

45. Chang KJ, Hoefs JC: Ascites and Encephalopathy. Current Opinion in Gastroenterology 1992;8:398-402.

46. Said HM, Morgan T, Hoefs JC: Effect of Chronic Portal Hypertension on Glutamine Transport in Rat Intestine. J Laboratory and Clinical Medicine 1993;122:64-68.

47. Said HM, Hoefs, JC: H+-Dependent 5-Methyletrahydrofolic Acid Transport in Basolateral Membrane Vesicles from Human Liver. American Journal of Clinical Nutrition 1993;58(1):80-4.

48. Fong TL, Morgan T, Phan C, Hoefs JC: Raising the Dose of Interferon does not Improve the Response in Chronic Hepatitis C. J Clin Gastroenterol 1995;20:42-44.

49. Hoefs JC, Chang K, Wang F, Kanel G, Morgan T, Braunstein P: The Perfused Kupffer Cell Mass: Correlation With Histology and Severity of CLD. Digestive Diseases and Sciences 1995:40(3):552-560.

50. Hoefs JC, Wang F, Kanel G, Braunstein P: The Liver-Spleen Scan as a Quantitative Liver Function Test: Correlation with Liver Severity at Peritoneoscopy. Hepatology 1995;22:1113-1121.

51. Hoefs JC, Wang F, Kanel G: Functional Measurement of the Non-Fibrotic Hepatic Mass in Cirrhotic Patients. Am J of Gastroenterol 1997;92:2054-2058.

52. Tong MJ, Reddy Rajender K, Lee William M, Pockros PJ, Hoefs JC, et al and the Consensus Interferon Study Group: Treatment of Chronic Hepatitis C With Consensus Interferon: A Multicenter, Randomized, Controlled Trial. Hepatology 1997;26:747-754.

53. Keeffe Emmet B, Hollinger B, [Hoefs, JC] and the Consensus Interferon Study Group: Therapy of Hepatitis C: Consensus Interferon Trials. Hepatology 1997;26(Suppl 1):101S-107S.

54. Heathcote E, Jenny L, Keefe Emmet B, Lee Samuel S, [Hoefs, JC], et al, and the Consensus Interferon Study Group: Retreatment of Chronic Hepatitis C With Consensus Interferon. Hepatology 1998;27:1136-1143.

Davis GL, Esteban-Mur R, Rustgi V, Hoefs JC, et al and the International Hepatitis Interventional Therapy Group: Recombinant Interferon alfa-2b (Intron A) alone or in combination with ribavirin (rebetol) for retreatment of interferon relapse in chronic hepatitis C. NEJM. 1998;339, 21: 1493-99.

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK, [Hoefs JC] et al, for the Hepatitis Interventional Therapy Group; Interferon Alfa-2b Alone or in Combination With Ribavirin as Initial Treatment for Chronic Hepatitis C. NEJM 1998;339, 21: 1485-92.

Lee WM, Reddy KR, Tong M, Black M, Van Leeuwen DJ, Hollinger FB, Mullen KD, Pimstone N, Albert D, Gardner S, [Hoefs JC] and the Consensus Interferon Group. Early hepatitis C virus RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 1998;28: 1411-1415.

Pockros PJ, Tong M, Lee WM Van Leeuwen DJ, Keeffe EB, Bala K, Killenberg PG, Foust RT, Rosenblate HJ, Payne KM, Fromm H, Lesesne HR, Black M, [Hoefs JC], and the Consensus Interferon Group. Relationship between biochemical and virological responses to interferon therapy of chronic hepatitis C infection. Journal of Viral Hepatitis 1998;5: 271-276.

Bonkovsky HL, Wooley JM, [Hoefs JC], and the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999;29: 264-270.

Hoefs JC, Wang FW, Walker B, Kanel G. A novel, simple method of functional spleen volume calculation by liver-spleen scan. J Nuc Med. 1999;40:1745-55.

61. Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K, Everson GT, Hoefs JC, et al, and the Consensus Interferon Study Group: Biochemical and Viral Response to Consensus Interferon (CIFN) Therapy in Chronic Hepatitis C Patients: Effect of Baseline Viral Concentration. Amer Jour of Gastroenterology. 1999;94:3583-8.

63. Everson GT, Jensen DM, Craig JR, Leeuwen D, Bain VC Ehrinpreis MN, Albert D, Joh T, Wit K, [Hoefs JC], and the Concensus Interferon Study Group: Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, and nonfibrotics. Hepatology. 1999;30:271-6.

64. Heathcote EJ, James S, Mullen KD, Hauser SC, Rosenblate H, Albert JR DC, [Hoefs JC] and the Concensus Interferon Group: Chronic HCV patients with breakthroughs during interferon treatment can successfully be retreated with concensus interferon. Hepatology 1999;30:562-6.

65. Pockros PJ, Bain VG, Hunter EB, Conrad A, Balart LA, Hollinger FB, Albert D, [Hoefs JC] and the Concensus Interferon Group: A Comparison of RT-PCR and bDNA assays for hepatitis C virus in patients receiving interferon treatment. Journal of Viral Hepatitis 1999;2:145-150.

66. Keeffe EB, Dusheiko GM, Tong MJ, Hollinger FB, Heathcote EJ, McHutchison J, Albert D,[Hoefs JC]. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group. Cytokines Cell Mol Ther. 1999 ;5(4):211-6.

67. Keeffe EB, Dusheiko GM, James SP, Mullen KD, Everson GT, Pimstone NR, Donovan J, Albert D,[Hoefs JC]. . Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group. Cytokines Cell Mol Ther. 1999;5(4):207-10.

68. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J, Hoefs J. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology. 2000;119(5):1317-23.

69. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34(2):395-403.

70. Hoefs JC, Sheikh M, Guererro HJ Milne N: Factors affecting the quantitative liver spleen scan in normal individuals. Digestive Diseases and Sciences 2005; 50:283-9

71. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, Patch D, Soriano G, Hoefs J, Navasa M. Sepsis in Cirrhosis - Report on the 7th Meeting of the International Ascites Club. Gut 2005: 54(5):718-25.

72. Zell J, Hoefs J, Ou S-H, Chang J, Yoon E. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anti Cancer Drugs 2005; 16:83-5

73. Hoefs JC, Chen PT, Lizotte P. Non-invasive Evaluation of Liver disease Severity. Clin of Liver Dis Dec 2006; 10: 535-562.

74. Hoefs J, Aulakh VS. Treatment of chronic HCV infection in special populations. Int J Med Sci. 2006;3 (2):69-74.

75. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany MG, Morishima C; HALT-C Trial Group. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology. 2006;131(5):1440-51.

76. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006 Dec;44 (6):1675-84.

77. Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, HoefsJC and the HALT-C Trial Group. Noninvasive Measurement Of Portal-Systemic Shunting In Patients With Fibrosis Or Cirrhosis Due To Chronic Hepatitis C: The Minimal Model For Measuring Cholate Clearances And Shunt In Man. Alimentary Pharmacology & Therapeutics 2007; 26:401-410

78. Hoefs JC, Morgan TR. 72 weeks of treatment for patients with partial EVR? (editorial). Hepatology 2007; 46:1671-4.

79. Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, Kugelmas M, Doherty MC, Wright EC, and the HALT-C Trial Group The Spectrum of Hepatic Functional Impairment in Patients with Fibrosis and Compensated Cirrhosis Due to Chronic Hepatitis C: Results from the HALT-C Trial. Alimentary Pharmacology & Therapeutics 2008; 27(9):798-809.

80. Everson GT, Shiffman, ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, DeSanto JL, Curto TM, Wright EC, and the HALT-C Trial Group. Quantitative Tests of Liver Function Measure Hepatic Improvement after Sustained Virologic Response: Results from the HALT-C Trial. Aliment Pharmacol Ther. 2009 Mar; 29(5): 589-601.

81. Lok AS, Everhart JE, Chung RT, Kim H-Y, Everson GT, Hoefs JC, Greenson JK, Sterling, RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C, and the HALT-C Trial Group. Evolution of Hepatic Steatosis in Patients with Advanced Hepatitis C: Results from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2009 Jun;49(6):1828-37.

82. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG, and the HALT-C Trial Group. Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology 2009 Dec; 137(6):1986-94. Epub 2009 Sep 10.

83. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R, HALT-C Trial Group. Coffee Intake is Associated with Lower Rates of Liver Disease Progression in Chronic Hepatitis C. Hepatology. 2009 Nov;50(5):1360-9. Comment in Hepatology. 2009 Nov;50(5):1673, author reply 1673.

84. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Prognostic Value of Ishak Fibrosis Stage: Findings from the HALT-C Trial Hepatology. 2010 Dec;51(2):585-94

85. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim H, Lee WM, Bonkovsky HL, Dienstag JL, and the HALT-C Trial Group Des-gamma-carboxy Prothrombin and Alpha fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma Gastroenterology 2010 Feb; 138: 493-502.

86.

Submitted:

87. Hoefs JC, Aulakh VS, DeRosa V. LKM Antibody Positive Autoimmune Hepatitis Induced by Treatment of Chronic Hepatitis C Hepatology (submitted)

88. Hoefs JC, Lizotte P, Newcomb R. The Platelet count in Patients with CLD: hepatic function or portal hypertension? Hepatology (submitted)

89. Hoefs JC, Herron TJ, Shieh YL, Aulakh VS, Newcomb R, Lizotte P. Hepatic Voxel Distribution: A Novel Method of Detecting Cirrhosis Enhancing the Quantitative Liver-Spleen Scan.

90. Hoefs JC, Kanel G, Rajan S, Becker R, Goodman Z. Hoefs-Kanel scoring for hepatic fibrosis: validation and correlation with quantitative digital morphometry. Alimentary Pharmacology & Therapeutics (submitted)

NON PEER REVIEW PUBLICATIONS

1. Hoefs JC, Peters RS, Redeker AG, Tong MJ, Mosley JW, Reynolds TB: Specialty Conference: Chronic Hepatitis-B. West Jour Med 128:305-317, 1978.

2. Lindsay K, Reynolds TB, Hoefs JC, San Marco ME: Specialty Conference: Ascites. West Jour Med 134 (5):414-423, 1981.

Hoefs JC, Runyon B: Spontaneous Bacterial Peritonitis. Disease-A-Month 31 (9):3-48, 1985.

Hoefs JC: UTP-Unit #33 Ascites. Undergraduate Teaching Project in Gastroenterology and Liver Disease. American Gastroenterological Association, February 1998.

PARTICIPATION IN BOOKS

Hoefs JC, Jonas G, Sarfeh IJ. Diagnosis and Hemodynamic Evaluation of the Patient with Portal Hypertension. In: Surgical Clinics of North America. Philadelphia: W.B. Saunders Co., 267-289, 1990.

Hoefs JC, Jonas G. Spontaneous Bacterial Peritonitis. In: Taylor MB, Gollan JL, Peppercorn MA, Steer M, & Wolfe MM (Eds.) Gastrointestinal Emergencies. Baltimore: Williams & Wilkins, pp. 351-357, 1991.

3. Hoefs JC. Gastrointestinal Symptoms, Clinical Interpretations: Ascites. Gewirtzman A, ed., Philadelphia, PA., B.C. Decker, Inc. Chapter 11, pages 185-208; 1991.

4. Hoefs JC, Jonas GM. Diagnostic Paracentesis. In: Advances in Internal Medicine, pp. 391-409, 1992.

5. Hoefs JC. The Hepatorenal Syndrome. In: Bockus Gastroenterology, Haubrich, ed., 5th ed. Ch. 105, 1993.

Hoefs JC: Portal Hypertension. In: Gitnick G, ed., Principles and Practice of Gastroenterology and Hepatology. New York: Elsevier, 1988. Revised 1993, 1994.

7. Hoefs JC, Koobatian Gregory J.: "Cholecystitis". In: Handbook of Obstetrics, Gynecology and Primary Care. Mosby Year book, Inc. St. Louis: pp. 543-547, 1998.

8. Hoefs JC, Rodes Juan, Schrier Robert W, Gines Pere, Arroyo Vicente. Characteristics of cirrhotic ascites. In: The Liver and The Kidney, Blackwell Scientific, 1998.

9. Hoefs JC, Alagiozian-Angelova V, Khatibi A. Management of Spontaneous Bacterial Peritonitis. In: Krawitt EL (Ed.). Medical Management of Liver Disease. New York: Marcel Dekker, Inc., pp. 531-543 1999.

10. Hoefs JC. Characteristics of Ascites. Chapter 2 In: Ascites and Renal Disfunction in Liver Disease, Blackwell Science, pp. 14-35, 1999.

ABSTRACTS

1. Renner IG, Juttner HU, Hoefs JC, Redeker AG: The demonstration of HBsAG in pure pancreatic juice obtained by ERCP. Gastroenterology 1976;71:A-32.

2. Hoefs JC: High protein ascites: A predictable accompaniment of diuresis. Clin Res 1977;25:A-152.

3. Zipser R, Hoefs JC, Speckart P, Zia P, Horton R: Prostaglandins: A critical modulator of renin release, blood pressure and renal function in liver disease. Clin Res 1977;25:A-151.

4. Renner IG, Reitherman R, Hoefs JC, Douglas AP: The hepatic contribution to serum amylase levels. Gastroenterology 1977;72:A-96.

5. Hoefs JC: Transition to high protein cirrhotic ascites during diuresis. Gastroenterology 1977;73:A-27.

6. Hoefs JC: Determinants of ascitic fluid protein in cirrhosis. Clin Res 1978;26:A-151.

7. Hoefs JC: Portal pressure estimation by ascitic fluid analysis. Gastroenterology 1978;74:1168.

8. Hoefs JC, Sakimura I, Reynolds T: Direct measurement of intrahepatic shunting by the portal vein injection of microspheres. Gastroenterology 1979;75:A-77.

9. Pare P, Hoefs JC, Ascavai M, Reynolds TB: Portal and hepatic venous concentration of bile acids in liver disease. Clin Res 1979;27:A-77.

10. Kaufman RL, Hoefs JC, Quismorio FP Jr, Tong MJ: Circulating immune complexes in patients with alcoholic liver disease (ALD). Clin Res 1979;27:1-38.

11. Hoefs JC: Dilution across the portal capillary in man. Clin Res 1979;27:A-27.

12. Hoefs JC, Barnes T: Intraperitoneal clotting with the ascites of chronic liver disease. Gastroenterology 1979;76:1156.

13. Hoefs JC: The ascites to serum ratio of albumin as a diffusional marker for globulin in ascites. Gastroenterology 1979;76:1155.

14. Hoefs JC, Sapico FL, Canawati HN, Montgomerie JZ: Acute hepatic injury is an important prognostic factor in spontaneous bacterial peritonitis. Gastroenterology 1980;78:1307, 1980.

15. Hoefs JC: Control of ascites protein concentration. Gastroenterology 1980;79 (5-A):1025.

16. Hoefs JC, Canawati H, Sapico F, Montgomerie J, Hopkins R: On set of spontaneous bacterial peritonitis relative to the time of admission. Gastroenterology 1980;79 (5-A):1025.

17. Feller A, Rodman J, Hoefs JC, Cohen J: Estimation of intrinsic hepatic clearance (IHC) of Lidocaine (L) in liver disease. Gastroenterology 1981;80 (5-A):331.

18. Hoefs JC, Reynolds TB, Sakimura I, Pare P: A new method for the measurement of intrahepatic shunts. Hepatology 1981;1(5):516.

19. Hoefs JC, Reynolds T, Sakimura I, Pare P: The clinical correlations of intrahepatic shunting. Hepatology 1981;1(5):508.

20. Hoefs JC, Reynolds T, Sakimura I, Pare P: Intrahepatic shunting in 92 patients with liver disease. Hepatology 1981;1(5):516.

21. Hoefs JC, Reynolds T, Sakimura I, Pare P: The laboratory and special procedure correlates of intrahepatic shunting in patients with liver disease. Hepatology 1981;1(5):516.

22. Feller A, Reynolds T, Stuart C, Hoefs JC: Prediction of portal decompression surgery results by liver scan. Hepatology 1981;1(5):509.

23. Jemison-Smith P, Vaziri N, Hoefs JC, Pahl M, O'Donnell M, Thrupp L: Probable nosocomial transmission of Hepatitis B via diagnostic peritoneoscopy. International Congress, London 1984.

24. Runyon BA, Hoefs JC: Culture-negative neutrophilic ascites. Gastroenterology 1982;82(5):1242.

25. Runyon BA, Hoefs JC: Infected ascitic fluid - spontaneous versus secondary. Hepatology 1982; 2(5):685,1982.

26. Hoefs J: Bioavailability of endogenous products of the portal circula­tion. Gastroenterology 1983;84(5):1375.

27. Hoefs JC, Runyon B: Oncotic-hydrostatic balance between plasma and residual peritoneal fluid in the rabbit. Gastroenterology 1983;84(5):1376.

28. Hoefs JC: A new method for calculation of the portal fraction of blood flow. Gastroenterology 1983;84(5):1375.

29. Hoefs JC: A new method for estimating the ratio of endogenous cholylgycine extrahepatically shunted: evaluation in a dog model. Gastroenterology 1983;84(5):1375.

30. Runyon BA, Morrissey RL, Hoefs JC, Wyle FA: Opsonic activity of human ascitic fluid: a potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology 1983;3(5):840.

31. Aufrichtig D, Hoefs JC, Lottenberg S, Friedenberg R, Ferrari L, Rannalli R: A comparison of images derived from the envelope and instantaneous frequency of pulse echo signals: Liver Diseases. (Accepted) Radiology.

32. Runyon BA, Hoefs JC: Ascitic fluid neutrophil count and bacterial culture. Guides to efficacy of treatment of spontaneous bacterial peritonitis. Hepatology 1984;4(5):1022.

33. Cummings D, Hoefs JC, Runyon B, Ashhurst J, Canawati HN, Sapico FL, Weiner J, Montgomerie JZ: Determinants of hospital survival in patients with spontaneous bacterial peritonitis: Multi-variate discriminant analysis of prognostic factors. Hepatology 1984;4(5):1070.

34. Hoefs J, Aufrichtig D, Kanel G, Lottenberg S, Ferrari L: FM Ultrasound: A new technique for non-invasively assessing hepatic fibrosis. Hepatology 1984;4(5):1072.

35. Cummings D, Hoefs JC, Runyon B, Ashhurst J, Canawati HN, Sapico FL, Weiner J, Montgomerie JZ: Determinants of the outcome of an episode of spontaneous bacterial peritonitis: Multi-variate discriminant analysis of prognostic factors. Hepatology 1984;4(5):1071.

36. Runyon BA, Hoefs JC: Ascitic fluid chemical analysis before, during and after spontaneous bacterial peritonitis. Hepatology 1985;5(2):257-259.

37. Runyon BA, Hoefs JC, Canawati HN: Inadvertent gut perforation by the paracentesis needle: Characterization and natural history. Gastroenterology 1985;85(5):1689.

38. Runyon BA, Hoefs JC: Peritoneal lymphomatosis with ascites: a characterization. Gastroenterology 1985;85(5):1689.

39. Kutch J, Hoefs JC, Ranon U, Braunstein P, McCaulley M, Runyon B, Donner B, Friedlander H, Bridges B, Batra R: A new method to quantify reticuloendothelial shift of Tc99 sulfur colloid: Correlation with hepatic function. Gastroenterology 1985;88(5):1672.

40. Kutch J, Hoefs JC, Ranon U, Kanel G, Braunstein P, Bridges B, McCaulley M, Runyon B, Batra R, Donner B, Freidlander H: Quantitative shift in Tc99 sulfur colloid activity by liver-spleen scan, liver morphology and indocyanine green clearance. Gastroenterology 1985;88(5):1673.

41. Runyon BA, Hoefs JC: Ascitic fluid caused by massive liver metastases: its prevalence, characterization and treatment. Hepatology 1985;5(5):1000.

42. Runyon BA, Morrissey RL, Hoefs JC, Wyle FA: Opsonic activity of ascitic fluid and its relationship to protein concentration and the risk of spontaneous peritonitis. Hepatology 1985;5(5):1000.

43. Hoefs JC, Rector W, Reynolds T: Determinants of the fasting glycocholic acid levels in the cirrhotic man. Hepatology 1985;5(5):1042.

44. Hoefs JC, Rector W, Reynolds T: Simultaneous C14 glycocholic acid disappearance curves from artery and hepatic vein in 10 cirrhotic patients. Hepatology 1985;5(5):1041.

45. Hoefs JC, Rector W, Reynolds T: Determination of the portal function of hepatic blood flow in man using an extraction technique. Hepatology 1985;5(5):1041.

46. Hoefs JC, Lottenberg S, Kanel G, Aufrichtig D, Donner B, Batra R, Freidenberg RM: Attenuation: A preliminary assessment relative to hepatic fat and fibrosis. Hepatology 1985;5(5):1042.

47. Hoefs JC, Lottenberg S, Kanel G, Aufrichtig D, Donner B, Batra R, Freidenberg RM: Detection of hepatic fat with the FM ultrasound. Hepatology 1985;5(5):1041.

48. Hoefs JC, Lottenberg S, Aufrichtig D, Donner B, Kanel G, Batra R, Friedenberg R: Detection of hepatic fibrosis with the FM ultrasound: a prospective trial. Hepatology 1985;5(5):1041.

49. Ocariz J, Hoefs JC, Kanel G, Bridges R, Braunstein P: Can precise assessment of liver spleen scan parameters predict the course of biliary cirrhosis? Hepatology 1986;6(5):95.

50. Hoefs JC, Wang F, Braunstein P, Morgan T, Leach S . Determinants of the liver-spleen scan image. Hepatology 1988;8(5):1346.

51. Hoefs JC, Wang F, Braunstein P. Expression of bone marrow activity by liver-spleen scan. Hepatology 1988;8(5):1347.

52. Hoefs JC, Morgan T, Braunstein P, Wang F: Subjective Assessment of reticuloen­dothelial shift (RES) of sulfur colloid by liver-spleen scan: correlation with liver and spleen pixel ratio. Hepatology 1988;8(5):1347.

53. Jonas G, Hoefs JC, Leach S, Thrupp L. Liver-spleen scan reticuloendothelial shift (res) of sulfur colloid predicts the development of spontaneous bacterial peritonitis. Hepatology 1988;8(5): 1351.

54. Hoefs JC, Chang K, Wang F, Kanel G, Morgan T, Braunstein P. The Quantitative Liver-Spleen Scan is the most accurate liver test for CLD. Digestive Diseases Week 1992;5;184.

55. Said H, Hoefs JC, Reza M, Horne DW. Biotin Transport in Human Liver Basolateral Membrane Vesicles: A Carrier-Mediated, Na+ Gradient-Dependent Process. Digestive Diseases Week 1992;5;129.

56. Hoefs JC, Wang F, Braunstein P. The quantitative liver spleen scan (QLSS) in ascitic patients. Hepatology 1993;18(4):934.

57. Hoefs JC, Wang F, Kanal G, Morgan T, Braunstein P: The non-invasive estimate of peritonoscopy assessment of liver disease severity. Hepatology 1993;18(4): 933.

58. Said H, Morgan T, Hoefs JC: Effect of Chronic Portal Hypertension on Glutamine Transport in Rat Intestine.

59. Said H, Hoefs JC: H+ -Dependent 5-Methyletrahydrofolic Acid Transport in Basolateral Membrane Vesicles from Human Liver. Amer Jour of Clinical Nutrition 1993;58(1):80-4.

60. Hoefs JC, Wang, F, Kanel G, Jurim O, Busuttil R: Non-Invasive Estimation of the Perfused Hepatic Mass: Correlation with the Non-Fibrotic Mass in Native Liver After Transplant or at Autopsy. Hepatology 1994;20:(4);21.

61. Hoefs JC, Wang F. The Perfused Hepatic Mass in Normals: Comparison of Fasting and Post-Prandial Values. Hepatology 1994;20:(4);20.

62. Hoefs JC, Wang F, Walker B. A Simple Technique for Estimating the Functional Volume of the Spleen. Hepatology 1994;20:(4);1042.

63. Hoefs JC, Wang F. Validation of Two Liver Spleen Scan Techniques for Estimating Hepatic Size. Hepatology 1994;20:(4); 1041.

64. Hoefs JC, Wang F, Kanel G. Prospective Prediction of Liver Disease Severity at Peritoneoscopy by Quantitative Liver Spleen Scan (QLSS). Hepatology 1994;20:(4); 1044.

65. Hoefs JC, Wang F: The Perfused Hepatic Mass Estimated from the Quantitative Liver Spleen: Before and After Transplant. Hepatology 1994;20:(4); 1043.

66. Hoefs JC, Lee W. Does Hepatitis C Viral (HCV) Genotype or Initial HCV RNA Titer Predict Induction of Response to Interferon Alfa 2a in Chronic Hepatitis C? Hepatology 1995;22:(4); 278.

67. Hoefs JC: Retreatment Followed by Long Term maintenance Therapy of HCV Patients with Prior Complete Response to Interferon Followed by Relapse. Hepatology 1995;22:(4); 42.

68. Hoefs JC, Hoefs H, Wang F, Kanel G. Prognostic Value of the Perfused Hepatic Mass. Hepatology 1995;22:(4); 208.

69. Hoefs JC. The Impact of Spleen Volume on Sulfur Colloid Distribution. Hepatology 1995;22:(4); 1293.

70. Lee WM with the Hepatitis Study Group, Roche Pharma Research and Roche Molecular systems, Nutley and Somerville, NJ, and Univ. of Texas Southwestern Med School, Dallas TX: Neither Genotype no RNA Titer Predicts Interferon Alfa 2a Response in Chronic Hepatitis C. Hepatology 1995;22(4);278.

71. Krawitt EL, Blatt LM, Tong MJ, Lee WM, et al., and the Consensus Interferon Study Group, Univ of Vermont, Burlington, BT, Amgen Inc., Boulder Co and the CIFN study sites: Biochemical and Virological Response to Consensus Interferon (CIFN) in Low viral titer chronic HCV patients. Hepatology 1996;24(4):1632.

72. Jensen DM, Blatt L, Tong MJ, Lee WM, et al., and the Consensus Interferon Study Group, Univ of Vermont, Burlington, BT, Amgen Inc., Boulder Co and the CIFN study sites: Treatment of high viral titer chornic HCV patients with consensus interferon (CIFN) Results in a significantly greater number of sustained HCV RNA Responders as compared to treatment with interferon-alpha 2b. Hepatology 1996;24(4):593.

73. Reddy R, Blatt LM, Conrad, MJ, Tong J, et al., and the Consensus Interferon Study Group: Genotype distribution in 815 chronic HCV infected patients in North America. Gastroenterology 1996;2038:A-510.

74. Lee WM, Van Leeuwen DJ, Keeffe E, et al., and the Consensus Interferon Study Group: Relationship between biochemical and virological response to type 1 interferon therapy of chronic HCV infection. Hepatology 1996;24(4):113.

75. Keeffe E, Blatt LM, Dusheiko G, et al, and the Consensus Interferon Study Group: Differential response to treatment with consensus interferon (CIFN) and IFN a-2b in chronic HCV patients infected with different HCV serotypes. Hepatology 1996;24(4): A594.

76. Pockros JP, Tong MJ, Lee WM, fan Leeuwen DJ, [Hoefs JC], et al., and the Consensus Interferon Study Group. Relationship between biochemical and virological response to type 1 interferon therapy of chronic HCV infection. Hepatology 1996;24(4): A113.

77. Craig JR, Blain VG, Black M, [Hoefs JC], et al., and the Consensus Interferon Study Group. Liver histology improvement is associated with ALT and HCV RNA response following treatment with consensus interferon (CIFN). Gastroenterology 1996;110(4): A1175.

78. Hollinger FB, Blatt LM, Tong MJ, [Hoefs JC], et al., and the Consensus Interferon Study Group. Differential response to treatment with consensus interferon (CIFN) and IFN-a 2b in chronic HCV patients infected with genotype 1a and 1b. Gastroenterology 1996;110(4): A1213.

79. Hollinger FB, Blatt, LM, Tong MJ, et al, and the Consensus Interferon Study Group: Baylor College of Medicine, Houston, TX; Amgen Inc., Thousand Oaks, CA; National Genetics Institute, Culver City, CA, and the Consensus Interferon Study Sites, USA and Canada: Differential response to treatment with consensus interferon (CIFN) and IFN-a 2b in chronic HCV patients infected with genotype 1a and 1b. Gastroenterology 1996;110(4):A1213.

80. Heathcote J, Keeffe E, Lee S, Feinman S, Tong M, and the Consensus Interferon Study Group: The Toronto Hospital, Toronto, Ontario; Stanford University, Stanford, CA; Health Science Center, Calgary, Alberta; Mount Sinai Hospital, Toronto, Ontario; Huntington Memorial Hospital, Pasadena, CA; Amgen Inc., CO and the Consensus Interferon Study Sites: Retreatment of Chronic HCV infection with a higher dose (15 ug) of consensus interferon (CIFN) produces sustained responses in non-responders and relapsers. Gastroenterology 1997;112(4):A1280.

81. Craig JR, Bain VG, Ehringpreis M, et al, and the Consensus Interferon Study Group: Liver histology improves in both cirrhotic and non-cirrhotic patients with chronic HCV infection following consensus interferon (CIFN) therapy. Gastroenterology 1997;112(4):A1248.

82.Jensen D, Shafritz D, Craig JR, Krawitt and the CIFN study Group: Non-responders to CIFN show clinically relevant improvements in liver histology. Gastroenterology 1997;112(4):A1294.